Abstract:Introduction Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated. Methods The ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis. Results ERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells. Conclusions Although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process.

The effects of estrogen on targeted cancer therapy drugs

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities

The Role of Estrogen and Estrogen Receptors in Chemoresistance.

Effects Of Estrogen On Breast Cancer Development: Role Of Estrogen Receptor Independent Mechanisms

The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy

Advances in Targeted Therapy for Overcoming Endocrine Therapy Resistance in Breast Cancer

Effect of Estrogen and Its Receptors on Tumor Development

Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment

Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future

Estrogen and Cancer

The immunomodulatory effects of endocrine therapy in breast cancer

162P Overcoming Resistance to Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Meta-Analysis of Randomized Clinical Trials

Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.

Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review

Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies

Estrogen Receptor Blockade Potentiates Immunotherapy for Liver Metastases by Altering the Liver Immunosuppressive Microenvironment

Effects of estrogen on diverse stem cells and relevant intracellular mechanisms

Post-transcriptional and epigenetic regulation of estrogen signaling